Leonie Klimpke
Direttore Finanziario/CFO presso Cavalry Ventures Management GmbH
Profilo
Leonie Klimpke is currently the Head of Finance at Cavalry Ventures Management GmbH since 2022.
Previously, she worked as a Finance Manager at Eternygen GmbH from 2016 to 2020.
Ms. Klimpke completed her undergraduate degree at Vrije Universiteit Amsterdam in 2010 and her graduate degree at École des Hautes Études Commerciales de Paris in 2014.
Posizioni attive di Leonie Klimpke
Società | Posizione | Inizio |
---|---|---|
Cavalry Ventures Management GmbH
Cavalry Ventures Management GmbH Investment ManagersFinance Cavalry Ventures Management GmbH (Cavalry) is a venture capital firm founded in 2015 by Rouven Dresselhaus. The firm is headquartered in Berlin, Germany. | Direttore Finanziario/CFO | 01/02/2020 |
Precedenti posizioni note di Leonie Klimpke
Società | Posizione | Fine |
---|---|---|
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Corporate Officer/Principal | 28/02/2020 |
Formazione di Leonie Klimpke
École des Hautes Études Commerciales de Paris | Graduate Degree |
Vrije Universiteit Amsterdam | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Cavalry Ventures Management GmbH
Cavalry Ventures Management GmbH Investment ManagersFinance Cavalry Ventures Management GmbH (Cavalry) is a venture capital firm founded in 2015 by Rouven Dresselhaus. The firm is headquartered in Berlin, Germany. | Finance |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Health Technology |
- Borsa valori
- Insiders
- Leonie Klimpke